Moonlake Immunotherapeutics (MLTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -121,244 | -44,079 | -64,506 | -4,543 | -91 |
| Depreciation Amortization | 1,385 | 370 | 165 | N/A | N/A |
| Accounts receivable | -1,786 | -840 | -68 | N/A | N/A |
| Accounts payable and accrued liabilities | 7,155 | 1,583 | -1,314 | N/A | N/A |
| Other Working Capital | -3,784 | -6,218 | -1,580 | 3,959 | -216 |
| Other Operating Activity | 1,687 | 6,405 | 11,410 | -28 | -10 |
| Operating Cash Flow | $-116,587 | $-42,778 | $-55,894 | $-611 | $-317 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -205,076 | -24,900 | -32,325 | N/A | N/A |
| PPE Investments | -520 | -285 | -16 | N/A | N/A |
| Other Investing Activity | 0 | 0 | 0 | 0 | -115,000 |
| Investing Cash Flow | $-205,595 | $-25,184 | $-32,341 | $N/A | $-115,000 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | -15,000 | N/A | N/A |
| Common Stock Issued | 52,540 | 482,454 | N/A | N/A | 112,700 |
| Other Financing Activity | -1,229 | -2,753 | 134,693 | -58 | 3,953 |
| Financing Cash Flow | $51,312 | $479,702 | $119,693 | $-58 | $116,653 |
| Exchange Rate Effect | 128 | -75 | 9 | N/A | N/A |
| Beginning Cash Position | 451,169 | 39,506 | 8,039 | 1,336 | N/A |
| End Cash Position | 180,427 | 451,169 | 39,506 | 667 | 1,336 |
| Net Cash Flow | $-270,743 | $411,664 | $31,467 | $-669 | $1,336 |
| Free Cash Flow | |||||
| Operating Cash Flow | -116,587 | -42,778 | -55,894 | -611 | -317 |
| Capital Expenditure | -520 | -285 | -16 | N/A | N/A |
| Free Cash Flow | -117,107 | -43,063 | -55,910 | -611 | -317 |